Streptococcus pneumoniae meningitis in Alberta pre- and postintroduction of the 7-valent pneumococcal conjugate vaccine

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 22, Issue 4, 2011, Pages 137-141

  Johnstone, Jennie ^a   Tyrrell, Gregory J ^b   Marrie, Thomas J ^c   Garg, Sipi ^d   Kellner, James D ^e   Hui, Stephanie ^f   Hurteau, Donna ^f   Lovgren, Marguerite ^f   Mangan, Carol ^f   Pitchko, Janice ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f NONE

Author keywords

Conjugate; Meningitis, streptococcus pneumoniae; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; DEXAMETHASONE; PENICILLIN G; PNEUMOCOCCUS VACCINE; VANCOMYCIN;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CANADA; CHILD; COHORT ANALYSIS; CORTICOSTEROID THERAPY; FEMALE; HUMAN; INCIDENCE; INFECTION RATE; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PRESCHOOL CHILD; SCHOOL CHILD; SEROTYPE; SEX RATIO; VACCINATION;

EID: 82955193341     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2011/179170     Document Type: Article

References (39)

1. Fedson DS, Scott JAG. The burden of pneumococcal disease among adults in developed and developing countries: What is said and is not known. Vaccine 1999;17(Suppl 1):S11-18. (Pubitemid 29366927)
2. Jit M. The risk of sequelae due to pneumococcal meningitis in high-income countries: A systematic review and meta-analysis. J Infect 2010;61:114-24.
3. Swartz MN. Bacterial meningitis - A view of the past 90 years. N Engl J Med 2004;351:1826-8. (Pubitemid 39426317)
4. Kellner JD, Scheifele D, Vanderkooi OG, et al. Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with Streptococcus pneumoniae in children in Calgary, Canada. Pediatr Infect Dis J 2008;27:526-32.
5. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997;337:970-6. (Pubitemid 27425953)
6. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptotoccus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 2001;285:1729-35. (Pubitemid 32259907)
7. National Advisory Committee on Immunization. Canadian Immunization Guide, 7th edn. Ottawa: Public Health Agency of Canada, 2006:93-5.
8. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: Recommendations of the Advisory Committee on Immunization Practices. Morb Mortal Wkly Rep 2000;49(RR-9):1-35.
9. Golmohammadi K, Nguyen TH, Hanrahan A, et al. Immunization coverage against invasive pneumococcal disease among children in the capital health region of Alberta. CCDR 2005;31:65-8.
10. Kellner J, Vanderkooi O, MacDonald J, et al. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: Update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009;49:205-12.
11. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46. (Pubitemid 36514704)
12. Kellner JD, Church DL, MacDonald J, Tyrrell GJ, Scheifele D. Progress in the prevention of pneumococcal infection. CMAJ 2005;173:1149-51. (Pubitemid 41634913)
13. Roche PW, Krause V, Cook H, et al. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 2008;32:18-30.
14. Vestrheim DF, Lovoll O, Aaberge IS, et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008;26:3277-81.
15. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006;295:1668-74.
16. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294:2043-50.
17. Tsai CJ, Grifin MR, Nuorti JP, Grijalva CG. Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin Infect Dis 2008;46:1664-72. (Pubitemid 351706762)
18. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009;360:244-56.
19. Health Surveillance. Population Projections for Alberta and its Health Regions, 2000-2030.
20. Canada Communicable Disease Report. Case definitions for diseases under national surveillance. Health Canada 2000;26S3:51
21. Facklam RR, Washington JA. Streptococcus and related catalase-negative gram-positive cocci. In: Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ, eds. Manual of Clinical Microbiology, 5th edn. Washington, DC: American Society for Microbiology, 1991:238-57.
22. Lund R, Henrichsen J. Laboratory diagnosis, serology and epidemiology of Streptococcus pneumoniae. In: Bergan T, Norris JR, eds. Methods in Microbiology. New York: Academic Press Inc, 1978:241-62.
23. National Committee for Clinical Laboratory Standards. Methods for dilution susceptibility testing for bacteria that grow aerobically; approved standard, sixth edition. Wayne: National Committee for Clinical Laboratory Standards 2003.
24. Kaplan SL, Mason EO, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004;113:443-9. (Pubitemid 38280781)
25. Ostergaard C, Konradsen HB, Samuelsson S. Clinical presentation and prognostic factors of Streptococcus pneumoniae meningitis according to the focus of infection. BMC Infect Dis 2005;5:93-103.
26. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39:1267-84.
27. van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004;351:18:1849-59.
28. Schwartz LE, Brown RB. Purulent otitis media in adults. Arch Intern Med 1991;266:2249-52.
29. De Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002;347:1549-56. (Pubitemid 35315835)
30. van de Beek D, de Gans J, McIntyre P, Prasad K. Steroids in adults with acute bacterial meningitis: A systematic review. Lancet Infect Dis 2004;4:139-43. (Pubitemid 38293137)
31. Mongelhuzzo J, Mohamad Z, Ten Have TR, Shah SS. Corticosteroids and mortality in children with bacterial meningitis. JAMA 2008;299:2048-55. (Pubitemid 351656586)
32. McIntyre PBMC, Gilmour R, Wang H. A population based study of the impact of corticosteroid therapy and delayed diagnosis on the outcome of childhood pneumococcal meningitis. Arch Dis Child 2005;90:391-6. (Pubitemid 40488679)
33. van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2007;24(1):CD004405
34. Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 2007;25:2194-212. (Pubitemid 46227685)
35. Scott DA, Komjathy SF, Hu BT, et al. Phase 1 of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 2007;25:6164-6. (Pubitemid 47088041)
36. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: A randomised double-blind efficacy study. Lancet 2006;367:740-8. (Pubitemid 43326292)
37. Hausdorff W, Hoet B, Schueman L. Do pneumococcal conjugate vaccines provide any cross-protection against 19A? BMC Pediatr 2010;10:4
38. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by non-vaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007;297:1784-92. (Pubitemid 46658647)
39. Moore MR, Gertz RE, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008;197:1016-27. (Pubitemid 351590031)